Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Stevanato Group S.p.A. (NYSE:STVN) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

Several research analysts recently issued reports on the company. Morgan Stanley dropped their price objective on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Citigroup dropped their target price on Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th.

Stevanato Group Price Performance

NYSE:STVN opened at €19.74 ($21.93) on Monday. Stevanato Group has a 12 month low of €16.56 ($18.40) and a 12 month high of €35.56 ($39.51). The company has a current ratio of 1.74, a quick ratio of 1.13 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average is €20.36 and its 200 day moving average is €22.95. The company has a market capitalization of $5.83 billion, a P/E ratio of 35.89, a P/E/G ratio of 5.51 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The company had revenue of €259.60 million for the quarter, compared to analysts’ expectations of €254.92 million. During the same quarter last year, the company earned $0.15 earnings per share. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities research analysts forecast that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STVN. Personal CFO Solutions LLC grew its position in Stevanato Group by 4.6% during the 4th quarter. Personal CFO Solutions LLC now owns 12,186 shares of the company’s stock worth $333,000 after purchasing an additional 534 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Stevanato Group by 54.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after buying an additional 1,086 shares during the period. Hilltop National Bank raised its position in shares of Stevanato Group by 34.3% during the 2nd quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock valued at $81,000 after buying an additional 1,122 shares during the period. Raymond James Trust N.A. raised its position in shares of Stevanato Group by 18.7% during the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after buying an additional 1,613 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Stevanato Group by 59.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock valued at $219,000 after buying an additional 4,441 shares during the period.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.